It’s an exciting & extremely busy time for Avacta – a leading life sciences firm developing innovative, new cancer treatments & powerful diagnostics.
Hence today, I was delighted to catchup with CEO Alastair Smith, who took me through the company's:
AVA6000 clinical trial wrt safety, dosing regimes, efficacy and ultimate usage. Start
preCISION enabled proteasome inhibitor AVA3996. 10:15
